托伐普坦缓释与速释制剂在常染色体显性多囊肾病中的随机试验
本研究为2期、多中心、随机、交叉、双盲、安慰剂对照试验,比较托伐普坦缓释制剂与速释制剂在ADPKD患者中的药代动力学、药效学和耐受性。结果显示缓释制剂呈剂量比例药代动力学,但耐受性较速释制剂无改善,且尿路效应耐受性个体间变异大。
要点
- 缓释托伐普坦20-120mg呈剂量比例药代动力学。
- 缓释120mg与速释90+30mg均使91.7%受试者尿渗透压<300mOsm/kg。
- 缓释制剂耐受性较速释制剂无改善。
核心结论
- 托伐普坦缓释制剂药代动力学可预测且呈剂量比例,但耐受性较速释制剂无改善。
- 高剂量缓释和速释组对尿路效应的耐受性存在显著个体间变异。
研究设计与样本
- 2期、多中心、平行组、随机、交叉、双盲、安慰剂对照试验(NCT01210560)。
- 两个研究组各12名受试者,每组3个交叉周期,给药7天。
主要发现
- 托伐普坦缓释20-120mg呈剂量比例药代动力学。
- 缓释120mg和速释90+30mg均使91.7%受试者尿渗透压<300mOsm/kg。
- 问卷评分变化对尿量变化敏感,但与尿量变化不成比例。
关键数值与推荐
- 尿渗透压<300mOsm/kg的受试者比例随剂量增加而升高。
- 缓释120mg与速释90+30mg的尿渗透压抑制比例均为91.7%。
临床怎么用
- 缓释制剂并未改善耐受性,临床选择制剂时需综合考虑个体耐受性差异。
局限性
- 样本量较小(每组12例),研究周期短(7天)。
- 个体间耐受性变异大,可能影响结果解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tolvaptan, for treatment of autosomal dominant polycystic kidney disease (ADPKD), is provided as immediate-release (IR) tablets administered twice daily in split-dose regimens to suppress urine osmolality to <300 mOsm/kg. A modified-release (MR) formulation was developed for once-daily (QD) dosing to increase compliance and mitigate urinary symptom burden. This phase 2, dose-ranging study (NCT01210560) compared pharmacokinetics, pharmacodynamics, and tolerability of several MR regimens with IR in patients with ADPKD. METHODS: This was a multicenter, parallel-arm, randomized, crossover, double-blind, placebo-controlled trial. Each of 2 study arms had 12 subjects and 3 crossover periods. Dose regimens were administered for 7 days; placebo-masked QD versus split-dose treatments. Endpoints included pharmacokinetic parameters, percentage of subjects with urine osmolality <300 mOsm/kg, urine volume, number of daily urine voids, and tolerability. RESULTS: Tolvaptan MR 20 to 120 mg exhibited dose-proportional pharmacokinetics. Percentage of subjects with spot urine osmolality <300 mOsm/kg increased with dose, with tolvaptan MR 120 mg and IR 90+30 mg each suppressing 91.7% of subjects below this level. Urinary burden on the ADPKD Nocturia Quality of Life, ADPKD Urinary Urgency, and ADPKD Urinary Frequency Questionnaires correlated with tolvaptan exposure, with high interindividual variability in responses. Changes in questionnaire scores were sensitive to changes in urine volume but not proportional to volume change, reflecting differences in subject tolerance to increased urine volume. CONCLUSION: Tolvaptan MR exhibited predictable and dose-proportional pharmacokinetics and no improvement in tolerability versus tolvaptan IR. Tolerability of the urinary effects of treatment within the high-dose MR and IR groups exhibited substantial interindividual variability.
引用
- Perrone RD, Chapman AB, Oberdhan D, et al. A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD. Kidney Int Rep. 2020. PMID: 32518861. doi:10.1016/j.ekir.2020.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。